España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Innate Pharma
IPHYF
OTCPK
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
Get Report
Comment
Innate Pharma (IPHYF) Forecast
News
Earnings
Innate Pharma (IPHYF) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Innate Pharma (OTC:IPHYF) Stock
Innate Pharma Stock (OTC: IPHYF)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Tuesday, July 06, 2021
Innate Pharma To Stop COVID-19 Trial With Avdoralimab After Mid-Stage Study Disappoints
Vandana Singh
Tuesday, June 22, 2021
Innate Pharma's Lacutamab Shows Clinical Responses In KIR3DL2-Expressing Mycosis Fungoides Patients
Vandana Singh
Innate Pharma Highlights Presentation Of Preliminary Data from TELLOMAK Trial
Bill Haddad
Wednesday, June 09, 2021
Innate Pharma To Present Data From Tellomak Trial At 16th International Conference on Malignant Lymphoma Jun. 22
Bill Haddad
Tuesday, February 09, 2021
Innate Pharma To Test Lacutamab In Relapsed/Refractory Peripheral T-Cell Lymphoma Patients
Vandana Singh
Monday, January 13, 2020
French Regulatory Agency Agrees lacutamab TEL...
Benzinga Newsdesk
Monday, October 07, 2019
Innate Pharma Announces 10.6M ADS IPO @Price to be Determined Following Bookbuilding Process
Charles Gross
Thursday, September 26, 2019
Innate Pharma Announces AstraZeneca to Advance Monalizumab to Phase III in Head and Neck Cancer
Charles Gross
Monday, January 11, 2016
Sanofi, Innate Pharma Collaborate on New Bispecific NK Cell Engagers in Immuno-Oncology
Benzinga
Sunday, January 10, 2016
Innate Pharma in-licenses OREGA biotech's first-in-class anti-CD39 checkpoint inhibitor program
Benzinga
Thursday, December 03, 2015
Innate Pharma Announces First patient dosed in Phase I trial of IPH4102
Benzinga
Wednesday, June 03, 2015
Astrazeneca, Innate Pharma Announce Global Co-Development and Commercialisation Collaboration for IPH2201 in Immuno-Oncology
Benzinga
Friday, April 24, 2015
Innate Pharma and AstraZeneca announce global agreement for IPH2201 in immuno-oncology
Benzinga
Thursday, April 16, 2015
Innate Pharma, Sanofi Announce Collaboration on Development of new Antibody Drug Conjugates
Benzinga
Monday, March 09, 2015
Innate Pharma Announces Investigators from NCIC CTG Presented Rationale, Protocol of IPH2201 Phase I/II Trial at TAT
Benzinga
Friday, December 19, 2014
Innate Pharma Announces First Phase II Trial with IPH2201 Open in Head and Neck Cancer
Benzinga
Monday, March 31, 2014
Innate Pharma Announces Bristol-Myers Squibb Conducting Phase I Trial with Lirilumab and Nivolumab in Selected Solid Tumors
Benzinga
Wednesday, November 20, 2013
Innate Pharma Raises €20.3M in Private Placement
Benzinga
Friday, November 15, 2013
Innate Pharma Initiates Iph43 Program to Develop First-In-Class Anti-Mica Antibody
Benzinga
